UCB SA (UCB.BR) Stock Price & Overview

EBR:UCB • BE0003739530

Current stock price

263.9 EUR
+5.2 (+2.01%)
Last:

The current stock price of UCB.BR is 263.9 EUR. Today UCB.BR is up by 2.01%. In the past month the price increased by 3.94%. In the past year, price increased by 93.62%.

UCB.BR Key Statistics

52-Week Range135.4 - 289.5
Current UCB.BR stock price positioned within its 52-week range.
1-Month Range238.9 - 278.4
Current UCB.BR stock price positioned within its 1-month range.
Market Cap
51.331B
P/E
26.42
Fwd P/E
24.99
EPS (TTM)
9.99
Dividend Yield
0.37%

UCB.BR Stock Performance

Today
+2.01%
1 Week
-4.04%
1 Month
+3.94%
3 Months
-0.64%
Longer-term
6 Months +6.15%
1 Year +93.62%
2 Years +111.88%
3 Years +212.60%
5 Years +242.46%
10 Years +303.83%

UCB.BR Stock Chart

UCB SA / UCB Daily stock chart

UCB.BR Stock Screens

UCB.BR currently appears in the following ChartMill screener lists.

Fastest Growing Stocks

UCB.BR is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.

CAN SLIM Stocks

UCB.BR is part of our CAN SLIM stock list, indicating it is suited for high growth momentum investing and is a technical leader.

High EPS Growth Stocks

UCB.BR occurs in our High EPS Growth Stocks screen list, indicating it is profitable, healthy and showing strong recent EPS growth.

UCB.BR Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to UCB.BR. When comparing the yearly performance of all stocks, UCB.BR is one of the better performing stocks in the market, outperforming 92.95% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
UCB.BR Full Technical Analysis Report

UCB.BR Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR. UCB.BR gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
UCB.BR Full Fundamental Analysis Report

UCB.BR Earnings

On February 26, 2026 UCB.BR reported an EPS of 6.46 and a revenue of 4.25B. The company beat EPS expectations (17.63% surprise) and beat revenue expectations (13.65% surprise).

Next Earnings DateJul 26, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported€6.46
Revenue Reported4.254B
EPS Surprise 17.63%
Revenue Surprise 13.65%
UCB.BR Earnings History

UCB.BR Forecast & Estimates

27 analysts have analysed UCB.BR and the average price target is 288.71 EUR. This implies a price increase of 9.4% is expected in the next year compared to the current price of 263.9.

For the next year, analysts expect an EPS growth of 5.7% and a revenue growth 11.6% for UCB.BR


Analysts
Analysts74.81
Price Target288.71 (9.4%)
EPS Next Y5.7%
Revenue Next Year11.6%
UCB.BR Forecast & Estimates

UCB.BR Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership
MSCI Europe Index STOXX Europe 600

UCB.BR Financial Highlights

Over the last trailing twelve months UCB.BR reported a non-GAAP Earnings per Share(EPS) of 9.99. The EPS increased by 100.6% compared to the year before.


Income Statements
Revenue(TTM)7.74B
Net Income(TTM)1.56B
Industry RankSector Rank
PM (TTM) 20.13%
ROA 8.58%
ROE 14.34%
Debt/Equity 0.2
Chartmill High Growth Momentum
EPS Q2Q%123.53%
Sales Q2Q%26.57%
EPS 1Y (TTM)100.6%
Revenue 1Y (TTM)25.83%
UCB.BR financials

UCB.BR Ownership

Ownership
Inst Owners40.85%
Shares194.51M
Float119.69M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
UCB.BR Ownership

UCB.BR Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
1SAN SANOFI 9.5698.562B
SAN SANOFI 9.5798.005B
SNW SANOFI 9.5897.981B
MRK MERCK KGAA 15.0250.065B
UNC UCB SA 24.9949.853B
1MRK MERCK KGAA 1546.695B
1BAYN BAYER AG-REG 9.3740.525B
BAYN BAYER AG-REG 9.3439.975B
IPN IPSEN 12.7813.628B
REC RECORDATI INDUSTRIA CHIMICA 16.9610.488B
TUB FINANCIERE DE TUBIZE N/A9.819B
VIRP VIRBAC SA 17.933.037B

Related stock screener links

View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Brussels Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find more growth stocks the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges

About UCB.BR

Company Profile

UCB logo image UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 10,117 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Company Info

IPO: 1987-01-02

UCB SA

Allee de la Recherche, 60

Anderlecht BRUXELLES-CAPITALE BE

Employees: 9765

UCB Company Website

UCB Investor Relations

Phone: 3225599999

UCB SA / UCB.BR FAQ

What does UCB do?

UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 10,117 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.


Can you provide the latest stock price for UCB SA?

The current stock price of UCB.BR is 263.9 EUR. The price increased by 2.01% in the last trading session.


Does UCB stock pay dividends?

UCB SA (UCB.BR) has a dividend yield of 0.37%. The yearly dividend amount is currently 1.39.


How is the ChartMill rating for UCB SA?

UCB.BR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Which stock exchange lists UCB stock?

UCB.BR stock is listed on the Euronext Brussels exchange.


How many employees does UCB SA have?

UCB SA (UCB.BR) currently has 9765 employees.


Can you provide the market cap for UCB SA?

UCB SA (UCB.BR) has a market capitalization of 51.33B EUR. This makes UCB.BR a Large Cap stock.